• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Initial Public Offering (IPO)

Medtronic to separate Diabetes business unit

May 21, 2025 By Sean Whooley

Medtronic Simplera Sync CGM with MiniMed 780G (1)

Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company. The medtech giant said the strategic decision can create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. The new company — […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Initial Public Offering (IPO), MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Medtronic

Beta Bionics to raise $114.4M in IPO

January 22, 2025 By Sean Whooley

Beta Bionics iLet Bionic Pancreas (2024)

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO). Earlier this month, the maker of the iLet bionic pancreas filed a registration statement with the SEC relating to a proposed IPO. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Initial Public Offering (IPO), MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Beta Bionics

Beta Bionics is proposing an IPO

January 7, 2025 By Sean Whooley

Beta Bionics iLet Bionic Pancreas (2024)

Beta Bionics announced today that it filed a registration statement with the SEC relating to a proposed initial public offering (IPO). The amount of shares of common stock included in the IPO and the price range remain undetermined. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market under the “BBNX” […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Technology, Wall Street Beat Tagged With: Beta Bionics

Fractyl Health goes the IPO route

February 2, 2024 By Chris Newmarker

This is the logo of Fractyl Health.

Fractyl Health — developer of medtech and gene therapies to reverse diabetes and obesity — began trading on the Nasdaq today under the symbol GUTS. Lexington, Massachusetts–based Fractyl Health priced its 7,333,333 shares of common stock at $15 per share, enabling it to bring in about $110 million from the IPO. The company expected the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Initial Public Offering (IPO) Tagged With: Fractyl Health

BD board approves Embecta diabetes business spinoff

February 1, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BD (NYSE:BDX) announced today that its board of directors approved the planned spinoff of its diabetes care business, Embecta. Franklin Lakes, N.J.-based BD confirmed in May 2021 that it planned to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it confirmed the […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Initial Public Offering (IPO), Wall Street Beat Tagged With: BD, embecta

Stevanato Group brings in upsized IPO worth $453.5M

August 17, 2021 By Sean Whooley

Stevanato Group

Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: Bexson Biomedical, infusion pump, initial public offering, IPO, shareholders, Stevanato Group, subcutaneous

Tenaya Therapeutics prices $180M IPO for targeted therapies

July 30, 2021 By Sean Whooley

Tenaya Therapeutics

Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of common stock worth $180 million. South San Francisco-based Tenaya develops therapies for rare generic disorders and more prevalent heart conditions through gene therapy, cellular regeneration and precision medicine. The company is actively exploring different routs of administration and different infusion- and injection-based methods […]

Filed Under: Auto-injectors, Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Regenerative Medicine, Wall Street Beat Tagged With: Tenaya Therapeutics

Pear Therapeutics to go public via merger with SPAC

June 22, 2021 By Sean Whooley

Pear Therapeutics

Prescription digital therapeutics pioneer Pear Therapeutics announced today that it will go public by merging with a SPAC called Thimble Point Acquisition Corp. Boston-based Pear Therapeutics’ combination with the special purpose acquisition company (SPAC), whose management team is associated with the Pritzker Vlock Family Office, will result in a combined company named Pear Holdings Corp. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Mergers & Acquisitions, Neurological, Patient Monitoring, Pharmaceuticals, Wall Street Beat Tagged With: Pear Therapeutics, peartherapeutics, Thimble Point Acquisition Corp.

Gyroscope Therapeutics launches IPO roadshow

May 3, 2021 By Sean Whooley

Gyroscope Therapeutics

Gyroscope Therapeutics announced today that it launched the roadshow for its initial public offering of nearly 7 million shares. London-based Gyroscope’s U.S. offering includes up to 6.75 million American Depository Shares (ADSs) representing 6.75 million ordinary shares, according to a news release. Gyroscope expects pricing for the IPO to range between $20 and $22 per […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Optical/Ophthalmic Tagged With: Gyroscope Therapeutics

CureVac stock soars after $213.3M IPO

August 17, 2020 By Sean Whooley

Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: coronavirus, COVID-19, CureVac

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS